Peptide research profile

Ipamorelin

Also known as Growth-hormone secretagogue · GHSR agonist

A synthetic pentapeptide ghrelin-receptor agonist designed to stimulate growth-hormone release with greater hormonal selectivity than earlier GHRPs.

  • Growth hormone signaling
Early human evidence3 referencesEducational use

Dosing literacy

Dosing & scaling, explained

The 300 mcg daily, five-days-on/two-days-off row is an unofficial recorded preset, not a regulator-approved regimen. This is educational source context—not a protocol or recommendation.

Scaling framework

How sourced amounts are organized

  1. Starting pointNot clinically established
    No validated titration window

    There is no regulator-approved starting dose for this research use. A low-looking number is not automatically safe.

  2. Recorded preset300 mcg / day
    Calculator library reference

    This is the range represented in the in-app protocol library. It describes the source record; it does not validate the regimen.

  3. Higher exposureNo validated wellness ceiling
    Risk and uncertainty increase

    Higher exposure is not established as more effective. Human pharmacokinetic and long-term safety data may be absent.

Drug amount and device markings are different quantities. The calculator converts mass into volume, syringe units, or pen clicks.

Schedule literacy

Patterns described in source material

  • 5 days on / 2 days off in the preset

    The cadence represented by the recorded calculator presets.

  • Human studies used study-specific IV or SC designs

    Published experiments may use a different route, formulation, timing, or population and should not be treated as interchangeable.

  • No universal schedule

    No single schedule has been validated across products or research contexts.

Clinical context

Human pharmacology confirms GH release, but no approved indication or long-term dosing schedule was established.

Research best practices

Storage, handling and interpretation

Lyophilized material

Keep cold, dry, and protected from light according to the manufacturer certificate or validated lab SOP.

After reconstitution

Use sterile technique, refrigerate as validated, and avoid repeated freeze–thaw cycles.

Traceability

Record lot, concentration, preparation date, and the identity/purity documentation used by the lab.

Research orientation

What researchers are exploring

These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.

  • 01

    Growth-hormone release

    Preclinical and early human pharmacology studies examine dose-dependent GH pulses.

  • 02

    Hormonal selectivity

    Discovery studies compare ACTH, cortisol, prolactin, and gonadotropin responses with other GHRPs.

  • 03

    Postoperative ileus

    Clinical development tested gastrointestinal recovery but did not establish efficacy.

  • 04

    Bone and body composition

    Animal studies examine downstream GH/IGF-1-related outcomes.

Evidence map

What the current evidence can support

Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.

  • Animal

    Selective secretagogue profile

    The foundational study showed GH release with less ACTH/cortisol response in animal models.

  • Human

    Early pharmacokinetic/pharmacodynamic work

    Healthy-volunteer studies characterized concentration and GH response.

  • Human

    Unsuccessful ileus development

    Phase 2 programs did not show meaningful improvement over placebo and development stopped.

Recorded protocol library

Amounts recorded for Ipamorelin

These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.

  • 01

    Dose · lower endpoint

    100 mcg

    Sign in for schedule, duration and source context.

  • 02

    Recorded reference

    300 mcg

    Sign in for schedule, duration and source context.

  • 03

    Dose · upper endpoint

    500 mcg

    Sign in for schedule, duration and source context.

Technical reference

Identity, limitations and unknowns

Molecular profile

Class
Selective growth-hormone secretagogue
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2
Amino acids
5
Approx. MW
711.9 Da
Origin / design
Synthetic GHSR-1a agonist

Important limitations

  • Short-term GH release is a biomarker, not evidence of body-composition or recovery benefit.
  • Long-term metabolic, neoplastic, and endocrine safety is not established for wellness use.
  • A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
  • Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.
  • Route, formulation, and population can make results from one study inapplicable to another use.

Curated sources

3 curated references

  1. Ipamorelin, the first selective growth hormone secretagogueEuropean Journal of Endocrinology · 1998 · Animal
  2. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in healthy volunteersJournal of Clinical Pharmacology · 1999 · Human
  3. Growth hormone secretagogues: history, mechanism of action, and clinical developmentReviews in Clinical and Experimental Metabolism · 2021 · Review

Related profiles